Day: September 11, 2025

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses. The private placement includes participation from both new and existing investors including Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare dedicated funds. The private placement will be for 4,000,002 shares of common stock...

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777’s best-in-class potential including data supporting its combination strategy. “These presentations highlighting our lead program, APG777, and earlier stage programs, underscore our commitment to bringing new treatment options that provide...

NEWARK, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, plans to announce its fiscal third quarter 2025 financial results after market close on Thursday, September 25, 2025. The Company also plans to host a conference call and webcast with the investment community to discuss the financial results that evening on Thursday, September 25, 2025, at 5:00 pm, Eastern Time. The live conference call webcast will be available in listen-only mode in the Investor Relations section of the Concentrix website under “Events and Presentations” at https://ir.concentrix.com/events-and-presentations A replay will also be available on the website following the conference call. About us: Powering a World That WorksConcentrix Corporation (NASDAQ: CNXC), a Fortune 500® company,...

MIAMI, Sept. 11, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today that Barry S. Logan, Executive Vice President, is scheduled to present at the 13th Annual Morgan Stanley Laguna Conference being held at the Ritz Carlton, Laguna Niguel on Thursday, September 11, 2025 at 4:50 p.m. (PDT). Internet users can listen to a live webcast of the presentation at the Investor Relations section of Watsco’s website at http://www.watsco.com. About Watsco Watsco operates the largest distribution network for heating, air conditioning and refrigeration (HVAC/R) products with locations in the U.S., Canada, Mexico, and Puerto Rico, and on an export basis to Latin America and the Caribbean. Watsco estimates that over 375,000 contractors, technicians, and installers visit or call one of its 701 locations each year to get information,...

Leadership transition comes as the Company explores digital treasury strategies to complement its integrated energy model WOODS CROSS, Utah, Sept. 11, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company, today announced the appointment of Marcus Laun as Interim Chief Executive Officer. Mr. Laun, a co-founder of the Company with more than 25 years of capital markets experience, has held senior roles in finance and advised on digital asset initiatives such as tokenization and exchange development. As Interim CEO, he will guide Sky Quarry through its next stage of growth with a focus on sustainable operations and the advancement of a digital treasury strategy. These initiatives are intended to broaden potential sources of capital, expand...

MONTREAL, Sept. 11, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a Quebec-based technology company driving innovation in advanced materials and critical process development, is pleased to announce it has been awarded up to $3 million in funding by the Government of Canada. This investment comes from the Energy Innovation Program’s Battery Industry Acceleration call for proposal, administered by Natural Resources Canada. The funding will help cover the capital costs and accelerate the building HPQ’s first 50-tonne-per-year continuous production system to manufacture silicon-based material for lithium-ion batteries. Developed in collaboration with technology partner Novacium [1], this material is at the core of HPQ ENDURA+ commercial 18650 (4,000 mAh) and 21700 (6,000 mAh)...

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to host investor conference call and webcast today at 8:30 am EDT SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc....

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) — Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present clinical and preclinical data from its portfolio of next-generation ultra-long acting, scalable, and combinable therapies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held September 15-19, 2025, in Vienna, Austria. “As we progress our pipeline of ultra-long acting next-generation nutrient-stimulated hormone, or NuSH, therapies, we are encouraged by the opportunity to leverage our investigational medicines both as monotherapies and in combination with each other,” said Steve Marso, M.D., Chief Medical Officer at Metsera. “Our late-breaker highlights the initial clinical results...

TORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE; FSE: PNX) (“Pasinex” or the “Company”) today announced it has executed a Share Transfer and Settlement Agreement (the “Agreement”) with Kurmel Holding A.S., Akmetal Dis Ticaret Madencilik Sanayi ve Ticaret A.Ş. Akmetal Madencilik Sanayi ve Ticaret A.Ş. and Birant Kurmel (all together “Kurmel Holding”), Pasinex Arama ve Madencilik A.Ş. (“Pasinex Arama”) and Horzum Maden Arama ve İşletme A.Ş. (“Horzum A.Ş.”). Under the Agreement, Kurmel Holding will transfer its 50% shareholding in Horzum A.Ş. to Pasinex Arama. Completion of the share transfer is subject to approval by Türkiye’s General Directorate of Mining and Petroleum Affairs (“MAPEG”) and other customary corporate and registration steps. Upon receipt of approvals and completion of registrations,...